Less Ads, More Data, More Tools Register for FREE

Pin to quick picksACRL.L Regulatory News (ACRL)

  • There is currently no data for ACRL

Board Changes

5 Feb 2018 07:00

RNS Number : 8555D
Accrol Group Holdings PLC
05 February 2018
 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

5 February 2018

Accrol Group Holdings plc("Accrol" or the "Company")BOARD CHANGES

Appointment of New Chairman and Interim Chief Financial Officer

 

Accrol Group Holdings plc (AIM: ACRL), the AIM-listed leading independent tissue converter, is pleased to announce that Dan Wright has been appointed Executive Chairman, moving from Independent Non-Executive Director with immediate effect.

 

Dan replaces Peter Cheung, who stepped down from the Board as Executive Chairman with effect from 3 February 2018 and has left the Company to focus on his other roles.

 

Peter Cheung said: "Having overseen the appointment of our new CEO, Gareth Jenkins, Dan Wright as NED and the strengthening of the management team, I remain optimistic about the future of the business. I would like to thank our customers, shareholders, and the Board for their support."

 

The Company is also pleased to announce that Martin Leitch, who joined the operational board on 20 November 2017, has been appointed to the Board as Interim Chief Financial Officer with immediate effect.

 

Martin is an international finance executive with almost 40 years' experience in both publicly quoted and private equity owned groups. He is a Chartered Accountant and has over the last five years provided finance, strategy, corporate finance and other services to a number of international businesses, including Volac International and Constantia Flexibles. Prior to this period he was Chief Financial Officer at Innovia Films, Quest International and Antalis Group.

 

He began his corporate career at Pepsi-Cola International in 1993, having worked for Price Waterhouse in both the UK and US between 1979 and 1993. Martin is currently a Non-Executive Director of Millennium & Copthorne Hotels plc.

 

As previously announced, the Company is currently in the process of searching for a permanent Chief Financial Officer.

 

The Board now comprises:

 

· Dan Wright (Executive Chairman)

· Gareth Jenkins (Chief Executive Officer)

· Martin Leitch (Interim Chief Financial Officer)

· Joanne Lake (Independent Non-Executive Director)

· Stephen Hammett (Independent Non-Executive Director)

 

 

Gareth Jenkins, Chief Executive Officer of Accrol, said:

 

"I am delighted that Dan has agreed to head the Board of Accrol. He is an experienced operator with considerable knowledge of the business and a strong understanding of the mechanics of the industry. I, personally, look forward to working with him, as we pursue a successful turnaround of this business. On behalf of everyone at Accrol, I welcome him to the role of Chairman.

 

"We also welcome Martin, who joins the Accrol Board following a highly impressive period as part of the senior management team. Martin brings considerable financial skills and turnaround experience to the Board and I have no doubt that he will make a valuable contribution.

 

"On behalf of the Board, I thank Peter and we wish him well for the future."

 

Dan Wright, Chairman of Accrol, added:

 

"I am delighted to return to a leadership role on the Accrol board. I remain convinced of the strong market fundamentals that underpin Accrol's leading position in the discount sector and I look forward with confidence to helping address the people, process and cost pressures that have held the business back since IPO. I have found the team led by Gareth and recently reinforced by Martin and Don to be clear-thinking and dynamic and relish the prospect of working with them to build on the business' position with its customers and restore profitability and value for its shareholders."

 

Information on Martin required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies:

 

Angus Martin Leitch, aged 59, is currently a director of the following companies:

· Millennium & Copthorne Hotels plc

· Glenridding Associates Limited

 

In addition, Martin has held the following directorships in the past five years:

· Hunter Hall School

 

Martin has no interests in the share capital of Accrol Group Holdings plc.

 

There is no further information on Martin required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies.

 

For further information, please contact:

Accrol Group Holdings plc

Gareth Jenkins, Chief Executive Officer

+44 (0) 1254 278 844

Zeus Capital Limited (Nominated Adviser & Broker) 

Dan Bate / Andrew Jones

Tel: +44 (0) 161 831 1512

Dominic King / John Goold

Tel: +44 (0) 203 829 5000

Belvedere Communications Limited

Cat Valentine (cvalentine@belvederepr.com)

Tel: +44 (0) 7715 769 078

 

Kim van Beeck (kvbeeck@belvederepr.com)

Tel: +44 (0) 7759 893 045

 

Notes to Editors

 

Accrol Group Holdings plc, based in Lancashire, is a leading tissue converter and supplier of toilet rolls, kitchen rolls and facial tissues as well as other tissue products to the UK's largest retailers.

Accrol operates from three sites:

· A manufacturing, storage and distribution facility in Blackburn;

· A facial tissue plant, also in Blackburn; and

· A manufacturing, storage and distribution facility in Leyland.

In addition, the business has a storage and distribution facility in Skelmersdale, Lancashire.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUSOORWOAURUR
Date   Source Headline
27th Jan 20231:27 pmRNSTR-1
24th Jan 20237:00 amRNSHalf Year Results
24th Jan 20237:00 amRNSStrategic Review Outcomes
11th Jan 20237:00 amRNSNotice: Results, Strategic Review & Presentations
20th Dec 20227:00 amRNSDirector Dealing
28th Nov 20221:36 pmRNSLaunch of second ESG Report
21st Nov 20227:00 amRNSHalf Year Trading Update
18th Nov 20227:00 amRNSAwards under LTIP and PDMR dealing
18th Oct 20221:27 pmRNSResult of 2022 Annual General Meeting
23rd Sep 20227:38 amRNSNotice of AGM and Posting of Annual Report 2022
20th Sep 20224:41 pmRNSSecond Price Monitoring Extn
20th Sep 20224:36 pmRNSPrice Monitoring Extension
6th Sep 20227:00 amRNSAudited Final Results
10th Aug 20227:00 amRNSNotice of Final Results and Online Presentations
31st May 202212:21 pmRNSTR-1
17th May 20227:00 amRNSTrading Update - FY22 in line with expectations
10th May 202211:57 amRNSTR-1
7th Apr 20227:00 amRNSTR-1
15th Mar 20223:58 pmRNSTR-1
14th Mar 20227:00 amRNSUpdate on LTC Share Purchase Agreement
11th Mar 20224:41 pmRNSSecond Price Monitoring Extn
11th Mar 20224:36 pmRNSPrice Monitoring Extension
4th Mar 20227:00 amRNSDirector Dealing
24th Feb 20223:45 pmRNSTR-1
24th Feb 20227:00 amRNSAwards under LTIP and PDMR dealing
11th Feb 202212:40 pmRNSTR-1
3rd Feb 20221:59 pmRNSTR-1
2nd Feb 202211:08 amRNSTR-1
21st Jan 20222:42 pmRNSTR-1
18th Jan 20227:00 amRNSHalf Year Results
17th Jan 20226:18 pmRNSTR-1
17th Jan 20223:13 pmRNSTR-1
12th Jan 20227:00 amRNSTrading Update
16th Dec 20217:00 amRNSNotice of Results and Online Investor Presentation
20th Oct 20217:00 amRNSTrading Update
28th Sep 20219:46 amRNSLaunch of ESG Report
24th Sep 202111:59 amRNSResult of AGM
27th Aug 20211:32 pmRNSNotice of AGM and Posting of Annual Report 2021
28th Jul 20215:30 pmRNSTR-1
23rd Jul 20212:35 pmRNSDirector Share Purchase
23rd Jul 20212:31 pmRNSExercise of Options, Director Dealings and TVR
16th Jul 20214:37 pmRNSDirector Shareholding
14th Jul 20217:00 amRNSAudited Final Results
7th Jul 20217:00 amRNSNotice of Results and Online Investor Presentation
4th Jun 202110:38 amRNSTR-1
18th May 20214:41 pmRNSSecond Price Monitoring Extn
18th May 20214:36 pmRNSPrice Monitoring Extension
18th May 20212:06 pmRNSSecond Price Monitoring Extn
18th May 20212:00 pmRNSPrice Monitoring Extension
18th May 202111:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.